FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128896589> ?p ?o ?g. }

• W3128896589 endingPage "463" @default.
• W3128896589 startingPage "455" @default.
• W3128896589 abstract "Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive target in B-cell malignancy and is the subject of several therapeutic strategies. The anti-CD19, humanized, monoclonal antibody tafasitamab (MOR208) has an engineered, modified Fc region with increased affinity for Fcγ receptors, leading to increased cytotoxicity via natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis) in a promising approach.The development of tafasitamab is reviewed, together with the pharmacokinetics and clinical experience of tafasitamab in R/R DLBCL; clinical data have led to FDA approval and inclusion in NCCN treatment guidelines for tafasitamab in combination with lenalidomide in this indication.Patients with R/R DLBCL who have failed rituximab-containing regimens may be resistant to CD20-directed therapies; therefore, therapies with an alternative mode of action are of great interest in this setting. Tafasitamab, an anti-CD19 monoclonal antibody, in combination with lenalidomide has demonstrated promising efficacy for patients with R/R DLBCL who are ineligible for autologous stem cell transplantation. This could provide an alternative approach to classical chemotherapy-based regimens in the relapsed setting." @default.
• W3128896589 created "2021-02-15" @default.
• W3128896589 creator A5016655102 @default.
• W3128896589 creator A5046659441 @default.
• W3128896589 creator A5078342005 @default.
• W3128896589 creator A5086354986 @default.
• W3128896589 date "2021-02-15" @default.
• W3128896589 modified "2023-10-14" @default.
• W3128896589 title "Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma" @default.
• W3128896589 cites W1020989877 @default.
• W3128896589 cites W1985645817 @default.
• W3128896589 cites W1992950983 @default.
• W3128896589 cites W1992990182 @default.
• W3128896589 cites W2035676378 @default.
• W3128896589 cites W2060466778 @default.
• W3128896589 cites W2084433006 @default.
• W3128896589 cites W2096764404 @default.
• W3128896589 cites W2107894877 @default.
• W3128896589 cites W2109440389 @default.
• W3128896589 cites W2136060045 @default.
• W3128896589 cites W2136453261 @default.
• W3128896589 cites W2143562636 @default.
• W3128896589 cites W2153558008 @default.
• W3128896589 cites W2164819810 @default.
• W3128896589 cites W2236959863 @default.
• W3128896589 cites W2279127916 @default.
• W3128896589 cites W2521775567 @default.
• W3128896589 cites W2605009867 @default.
• W3128896589 cites W2744261860 @default.
• W3128896589 cites W2763229989 @default.
• W3128896589 cites W2763676229 @default.
• W3128896589 cites W2792232222 @default.
• W3128896589 cites W2809013389 @default.
• W3128896589 cites W2921072067 @default.
• W3128896589 cites W2924528896 @default.
• W3128896589 cites W2962711446 @default.
• W3128896589 cites W2963300099 @default.
• W3128896589 cites W2983147839 @default.
• W3128896589 cites W2983656034 @default.
• W3128896589 cites W2984385741 @default.
• W3128896589 cites W2985859616 @default.
• W3128896589 cites W2986154089 @default.
• W3128896589 cites W2986702822 @default.
• W3128896589 cites W2987374777 @default.
• W3128896589 cites W2989466518 @default.
• W3128896589 cites W2995900562 @default.
• W3128896589 cites W3032094827 @default.
• W3128896589 cites W3034162969 @default.
• W3128896589 doi "https://doi.org/10.1080/14712598.2021.1884677" @default.
• W3128896589 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8363059" @default.
• W3128896589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33554668" @default.
• W3128896589 hasPublicationYear "2021" @default.
• W3128896589 type Work @default.
• W3128896589 sameAs 3128896589 @default.
• W3128896589 citedByCount "19" @default.
• W3128896589 countsByYear W31288965892021 @default.
• W3128896589 countsByYear W31288965892022 @default.
• W3128896589 countsByYear W31288965892023 @default.
• W3128896589 crossrefType "journal-article" @default.
• W3128896589 hasAuthorship W3128896589A5016655102 @default.
• W3128896589 hasAuthorship W3128896589A5046659441 @default.
• W3128896589 hasAuthorship W3128896589A5078342005 @default.
• W3128896589 hasAuthorship W3128896589A5086354986 @default.
• W3128896589 hasBestOaLocation W31288965891 @default.
• W3128896589 hasConcept C126322002 @default.
• W3128896589 hasConcept C143998085 @default.
• W3128896589 hasConcept C203014093 @default.
• W3128896589 hasConcept C2776063141 @default.
• W3128896589 hasConcept C2776364478 @default.
• W3128896589 hasConcept C2778559949 @default.
• W3128896589 hasConcept C2779338263 @default.
• W3128896589 hasConcept C2780653079 @default.
• W3128896589 hasConcept C2911091166 @default.
• W3128896589 hasConcept C502942594 @default.
• W3128896589 hasConcept C71924100 @default.
• W3128896589 hasConceptScore W3128896589C126322002 @default.
• W3128896589 hasConceptScore W3128896589C143998085 @default.
• W3128896589 hasConceptScore W3128896589C203014093 @default.
• W3128896589 hasConceptScore W3128896589C2776063141 @default.
• W3128896589 hasConceptScore W3128896589C2776364478 @default.
• W3128896589 hasConceptScore W3128896589C2778559949 @default.
• W3128896589 hasConceptScore W3128896589C2779338263 @default.
• W3128896589 hasConceptScore W3128896589C2780653079 @default.
• W3128896589 hasConceptScore W3128896589C2911091166 @default.
• W3128896589 hasConceptScore W3128896589C502942594 @default.
• W3128896589 hasConceptScore W3128896589C71924100 @default.
• W3128896589 hasFunder F4320328062 @default.
• W3128896589 hasIssue "4" @default.
• W3128896589 hasLocation W31288965891 @default.
• W3128896589 hasLocation W31288965892 @default.
• W3128896589 hasLocation W31288965893 @default.
• W3128896589 hasOpenAccess W3128896589 @default.
• W3128896589 hasPrimaryLocation W31288965891 @default.
• W3128896589 hasRelatedWork W1598567296 @default.
• W3128896589 hasRelatedWork W1996279342 @default.
• W3128896589 hasRelatedWork W2149557304 @default.
• W3128896589 hasRelatedWork W2413015302 @default.
• W3128896589 hasRelatedWork W2416082333 @default.

• next